Clinical trial
A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors
NCT02831179 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- December 31, 2017
- Completion date
- February 29, 2020
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
functional pancreatic neuroendocrine tumor, malignant somatostatinoma, merkel cell carcinoma, metastatic adrenal gland pheochromocytoma, metastatic carcinoid tumor, multiple endocrine neoplasia type 1, multiple endocrine neoplasia type 2a, multiple endocrine neoplasia type 2b, neuroendocrine neoplasm, non-functional pancreatic neuroendocrine tumor, pancreatic glucagonoma, pancreatic insulinoma, recurrent adrenal cortex carcinoma, recurrent adrenal gland pheochromocytoma, recurrent merkel cell carcinoma, somatostatin-producing neuroendocrine tumor, stage iii adrenal cortex carcinoma, stage iii thyroid gland medullary carcinoma, stage iiia merkel cell carcinoma, stage iiib merkel cell carcinoma, stage iv adrenal cortex carcinoma, stage iv merkel cell carcinoma, stage iva thyroid gland medullary carcinoma, stage ivb thyroid gland medullary carcinoma, stage ivc thyroid gland medullary carcinoma, thymic carcinoid tumor, vip-producing neuroendocrine tumor, well differentiated adrenal cortex carcinoma, zollinger ellison syndrome